UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Leukemia, 2012-09, Vol.26 (9), p.2096-2102

2012

Volltextzugriff (PDF)

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Leukemia, 2009-06, Vol.23 (6), p.1054-1061

2009

Volltextzugriff (PDF)

Harmonization of molecular monitoring of CML therapy in Europe

Leukemia, 2009-11, Vol.23 (11), p.1957-1963

2009

Volltextzugriff (PDF)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Leukemia, 2017-11, Vol.31 (11), p.2529-2531

2017

Volltextzugriff (PDF)

Dispersion of a Point-Source Release of a Passive Scalar Through an Urban-Like Array for Different Wind Directions

Boundary-layer meteorology, 2011-06, Vol.139 (3), p.367-394

2011

Volltextzugriff (PDF)

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Leukemia, 2010-10, Vol.24 (10), p.1719-1724

2010

Volltextzugriff (PDF)

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

Leukemia, 2006-11, Vol.20 (11), p.1925-1930

2006

Volltextzugriff (PDF)

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Blood, 2004-11, Vol.104 (9), p.2926-2932

2004

Volltextzugriff (PDF)

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

Scientific reports, 2017-05, Vol.7 (1), p.2467-9, Article 2467

2017

Volltextzugriff (PDF)

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

Leukemia, 2015-01, Vol.29 (1), p.230-232

2015

Volltextzugriff (PDF)

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Leukemia, 2003-12, Vol.17 (12), p.2401-2409

2003

Volltextzugriff (PDF)

Spatial and Temporal Variability of the Concentration Field from Localized Releases in a Regular Building Array

Boundary-layer meteorology, 2016-05, Vol.159 (2), p.241-257

2016

Volltextzugriff (PDF)

Wind-Direction Effects on Urban-Type Flows

Boundary-layer meteorology, 2012-02, Vol.142 (2), p.265-287

2012

Volltextzugriff (PDF)

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1–PDFGRB fusion gene

Leukemia, 2016-06, Vol.30 (6), p.1402-1405

2016

Volltextzugriff (PDF)

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

British journal of cancer, 2013-09, Vol.109 (6), p.1593-1598

2013

Volltextzugriff (PDF)

Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

British journal of haematology, 1999-12, Vol.107 (3), p.587-599

1999

Volltextzugriff (PDF)

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

Leukemia, 2006-04, Vol.20 (4), p.664-670

2006

Volltextzugriff (PDF)

P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY

HemaSphere, 2022-06, Vol.6, p.615-616

2022

Volltextzugriff (PDF)

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA

International journal of laboratory hematology, 2010-12, Vol.32 (6p1), p.e222-e228

2010

Volltextzugriff (PDF)

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Leukemia, 2009-09, Vol.23 (9), p.1628-1633

2009

Volltextzugriff (PDF)

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Blood, 2022-09, Vol.140 (11), p.1200-1228

2022

Volltextzugriff (PDF)

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin

Leukemia, 2009-04, Vol.23 (4), p.819-820

2009

Volltextzugriff (PDF)

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials

PloS one, 2019-03, Vol.14 (3), p.e0214305-e0214305

2019

Volltextzugriff (PDF)

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Leukemia, 2010-05, Vol.24 (5), p.1102-1102

2010

Volltextzugriff (PDF)

1 – 25 von 1.771

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.342)
Mit Volltextzugriff
(1.392)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(651)
Life Sciences & Biomedicine
(369)
Humans
(260)
Physical Sciences
(250)
Physics
(222)
Biological And Medical Sciences
(116)
Technology
(114)
Hematology
(110)
Female
(105)
Medical Sciences
(104)
Male
(99)
Animals
(85)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(82)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(80)
Fusion Proteins, Bcr-Abl - Genetics
(72)
Materials Science
(70)
Middle Aged
(70)
Oncology
(70)
Adult
(69)
Chemistry
(68)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(539)
Publisher or Other Site
(489)
Ingenta
(450)
MEDLINE
(368)
Wiley Online Library
(262)
ScienceDirect
(260)
Journals@OVID
(259)
American Physical Society Journals
(203)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(189)
PROLA - Physical Review Online Archive
(184)
SAGE Premier Complete
(171)
IngentaConnect Journals
(136)
Nexis Uni
(96)
Springer Journals
(95)
Wiley Online Library Full Collection 2018
(84)
JSTOR All Journals
(75)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(73)
Nature Journals
(57)
Taylor & Francis Online
(48)
IEEE Xplore
(48)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(152)
The Sociological Review
(146)
Physical Review. C, Nuclear Physics
(88)
Physical Review Letters
(75)
Physics Letters. B
(42)
Biochemical Society Transactions
(34)
New Statesman
(33)
Leukemia
(27)
Nuclear Physics. A
(26)
The European Physical Journal. A, Hadrons And Nuclei
(25)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Harmonization of molecular monitoring of CML therapy in Europe

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Dispersion of a Point-Source Release of a Passive Scalar Through an Urban-Like Array for Different Wind Directions

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Spatial and Temporal Variability of the Concentration Field from Localized Releases in a Regular Building Array

Wind-Direction Effects on Urban-Type Flows

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1–PDFGRB fusion gene

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY

Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Suchergebnisse filtern